Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Innovent Biologics ( (HK:1801) ).
Innovent Biologics, Inc. announced the grant of 4,023,697 share options to 49 grantees, including directors and non-connected employees, as part of its 2024 Share Scheme. The options, which have a ten-year validity period, are subject to a vesting schedule and performance targets for non-independent directors, while independent directors are exempt from these targets to maintain their objectivity. This move aligns with the company’s remuneration policy and aims to incentivize key personnel, potentially impacting the company’s operational efficiency and market competitiveness.
More about Innovent Biologics
Innovent Biologics, Inc. is a biotechnology company incorporated in the Cayman Islands. The company is focused on the development, manufacturing, and commercialization of biologic medicines, primarily targeting the treatment of cancer and other major diseases.
YTD Price Performance: 28.82%
Average Trading Volume: 13,225
Technical Sentiment Signal: Sell
Current Market Cap: $9.66B
See more data about 1801 stock on TipRanks’ Stock Analysis page.